Abstract. D-mannoheptulose (MH) 
hepatic glycogenolysis may have contributed to the different blood glucose responses in fed and starved mice. The hyperglycaemia in fed mice was unaffected by pre-treatment with L-leucine, or p-hydroxymercuribenzoate (PMB), but was abolished by pre-treatment with tolbutamide, and by post-treatment with insulin. Treatment of fed mice with MH before alloxan caused a marked "initial" hyperglycaemia but no second hyperglycaemia, and thus no development of alloxan diabetes.
In starved mice injected with MH before alloxan there was an inhibition of the initial hyperglycaemia, but occurrence of a "second" hyperglycaemia, suggesting an absence of protection against the development of alloxan diabetes. The data show that alloxan diabetes may develop in the absence of an "initial" hyperglycaemia and a triphase blood glucose response. The hyperglycaemic action of MH in fed mice is believed to underlie the protection against alloxan toxicity.
Mannoheptulose (MH) administration to rats (Simon & Kraicer 1957; Simon et al. 1962 ) and rabbits (Coore et (Zawalich & Beidler 1973; Rossini et al. 1975) in vivo, and in rat (Tomita et al. 1974 ) and mouse (Idahl et al. 1977 ) islets in vitro. These studies have shown that MH partly (Tomita et al. 1974) (Boquist 1977 (Boquist , 1978 (Boquist , 1979b (Boquist 1979a) . This hyper¬ glycaemia is abolished by l.-leucine, but not by MH (Boquist 1979b (Fig. 3) . Pre-treatment with tolbutamide on Injection of insulin in fed mice 10 min after MH administration caused decreased blood glucose concentration at the 1 (53.1 ± 4.8 mg/100 ml; mean ± sem) and 2 (47.3 ± 5.0 mg/100 ml; mean ± Sem) h observation time, suggesting an abolishment of the hyperglycaemic response to MH. 
Discussion
The hyperglycaemic action of MH has been ascribed to a reversible block of insulin secretion and an acceleration of gluconeogenesis (Simon & Kraicer 1966 (Boquist 1979b ).
Since it is well-known that pre-treatment with glucose protects against alloxan toxicity, also in C57BL-mice in vivo (Boquist 1977) , it is believed that the protection against alloxan in group V is due to the hyperglycaemic action of MH in fed mice. The (Jain & Logothetopoulos 1976) .
Pre-treatment with l.-leucine protects against al-loxan (Boquist 1978) , and abolishes the hyperglyc¬ aemic response to PMB in fed mice (Boquist 1979b) . In the present study no (Boquist 1979b) , and the data in the present study show that pre-treatment with PMB does not affect MH-in¬ duced hyperglycaemia.
